STOCK TITAN

Silk Road Medical Inc - SILK STOCK NEWS

Welcome to our dedicated news page for Silk Road Medical (Ticker: SILK), a resource for investors and traders seeking the latest updates and insights on Silk Road Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Silk Road Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Silk Road Medical's position in the market.

Rhea-AI Summary
Silk Road Medical, Inc. (Nasdaq: SILK) will present at the BofA Securities 2024 Healthcare Conference on May 14, 2024, at 3:40 p.m. Pacific Time. The presentation aims to showcase the company's efforts in reducing the risk of stroke. Interested parties can access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences
-
Rhea-AI Summary
Silk Road Medical, Inc. (SILK) will announce its financial results for Q1 2024 on April 30th, 2024. The company focuses on stroke risk reduction. A webcast will be hosted by management at 1:30 p.m. PT / 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Silk Road Medical, Inc. (Nasdaq: SILK) has launched the ENROUTE Transcarotid Neuroprotection System PLUS, enhancing the TCAR portfolio with improved features for smoother insertion, greater precision, and a simplified prep experience. The company aims to strengthen neuroprotection during the TCAR procedure, reflecting its commitment to innovation in carotid disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
Rhea-AI Summary
Silk Road Medical (NASDAQ: SILK) and Genesis MedTech Group have signed an exclusive distribution agreement to introduce TCAR® core products in China. TCAR is a minimally invasive surgical procedure to treat carotid artery disease, reducing the risk of stroke and improving outcomes. The partnership aims to provide comprehensive solutions to patients in China, where stroke is a major health concern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
Rhea-AI Summary
Silk Road Medical, Inc. (SILK) launches Tapered ENROUTE Transcarotid Stent System in the US, expanding its TCAR offerings. The system aims to reduce stroke risk with tailored configurations for patient anatomy, offering physicians a diverse toolkit for carotid artery disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
none
-
Rhea-AI Summary
Silk Road Medical, Inc. (SILK) reported financial results for Q4 2023 and full year 2023, showing revenue growth driven by increased TCAR adoption. The company completed over 25,000 TCAR procedures in 2023, received expanded coverage for TCAR, and initiated market releases for new configurations. Despite revenue growth, operating expenses increased, leading to a net loss for both periods. The company projects revenue of $194-198 million for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
Rhea-AI Summary
Silk Road Medical, Inc. (Nasdaq: SILK) will report financial results for Q4 and full year 2023 on February 28th, 2024. The corresponding audio webcast will be hosted by company management at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Interested participants can register online and are encouraged to do so at least 15 minutes before the call. A live and replay version of the webcast will be available at https://investors.silkroadmed.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
conferences earnings
-
Rhea-AI Summary
Silk Road Medical, Inc. (Nasdaq: SILK) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.42%
Tags
conferences
-
Rhea-AI Summary
Silk Road Medical, Inc. (Nasdaq: SILK) reported a 19% increase in revenue for the third quarter of 2023, driven by increased TCAR adoption. The company also welcomed Chas McKhann as the new CEO, projecting 23% to 26% revenue growth for full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
Rhea-AI Summary
Silk Road Medical, Inc. has appointed Chas McKhann as Chief Executive Officer (CEO). McKhann brings over 25 years of experience in the medical device industry and has held leadership positions at several companies. Silk Road focuses on reducing the risk of stroke and aims to establish Transcarotid Artery Revascularization (TCAR) as the standard of care in carotid artery disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
none
Silk Road Medical Inc

Nasdaq:SILK

SILK Rankings

SILK Stock Data

712.98M
38.29M
5.94%
105.6%
10.44%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Sunnyvale

About SILK

silk road medical, inc. is a privately held company located in sunnyvale, california, dedicated to preventing the devastating burden of stroke through surgical innovation. the company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. for more information on the company, visit our website at http://silkroadmed.com/. the transcarotid artery revascularization (tcar) procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. th